SCHEMBL3018571

SCHEMBL3018571

Cc1cc(C)cc(Cc2csc(N3CCN(S(=O)(=O)c4ccc(Cl)cc4Cl)CC3)n2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 2/20 0.45
LPAR1 Q92633 1/20 0.43
LPAR2 Q9HBW0 1/20 0.43
HSD11B1 P28845 2/20 0.41
KDM2B Q8NHM5 1/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
KDM4E B2RXH2 2/20 0.38
POLB P06746 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
GAA P10253 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
LMNA P02545 2/20 0.38
CNR1 P21554 1/20 0.38
CNR2 P34972 1/20 0.38
MAPK1 P28482 1/20 0.38
NPSR1 Q6W5P4 2/20 0.37
ALDH1A1 P00352 1/20 0.37
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3013342 0.92 TRPV4 (0.45) TRPV4LPAR1LPAR2HSD11B1KDM2B
SCHEMBL3006655 0.92 MAPT (0.45) KDM2BNPC1RAB9ASMN1; SMN2GAA
SCHEMBL3008696 0.92 TRPV4 (0.47) TRPV4LPAR1LPAR2HSD11B1KDM2B
SCHEMBL3009094 0.91 TRPV4 (0.47) TRPV4LPAR1LPAR2HSD11B1KDM2B
SCHEMBL3016879 0.90 HCRTR1 (0.40) TRPV4LPAR1LPAR2HSD11B1SMN1; SMN2
SCHEMBL3115852 0.90 ALDH1A1 (0.43) RAB9ASMN1; SMN2GAAMEN1KMT2A
SCHEMBL3021382 0.90 TRPV4 (0.48) TRPV4LPAR1LPAR2HSD11B1KDM2B
SCHEMBL3009591 0.89 LPAR1 (0.42) TRPV4LPAR1LPAR2HSD11B1KDM2B
SCHEMBL3011309 0.89 CHRM4 (0.43) SMN1; SMN2MEN1KMT2ALMNAMAPK1
SCHEMBL3017217 0.89 LPAR1 (0.44) TRPV4LPAR1LPAR2HSD11B1KDM2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA TRPV4 2844/4885LPAR1 2066/4885LPAR2 1732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.